Drug makers stalling on 2012 business plan

Weighed down by the imminent large price cuts and Assembly’s ratification of the new Korea-U.S. free trade agreement, domestic pharmaceutical firms are delaying the formulation of their business plans for next year.

At this time of the year, Korean companies usually flesh out key components of their plans, including profit goals and investment scale. But now, they say that things are put on ...